Biotech Specialty Pharma

Cognoptix, Inc.

20 Main Street
Acton, MA 01720 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description develops technology to detect Alzheimer's disease.

Management Paul Hartung, President and CEO; Gerald D. Cagle, PhD, Chief Operating Officer; Tom Trometer, Chief Financial Officer; Anne Cameron, PhD, Director, Marketing and Clinical Strategy; Ginny Kapner, General Counsel;

Click here for Financial Data
Keywords: Diagnostics, Alzheimer's, Alzheimer, Alzheimers, biotech, eye, Ophthalmology, test


Updated: Oct. 22, 2015


Cognoptix, a privately held medical technology company headquartered in Acton, Mass., is focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early de......view more

Products / Services

Fluorescent Ligand Scanning (FLS) is a technique in which a compound composed of beta amyloid-specific small molecules is dropped into a patient's eye, which is scanned by the SAPPHIRE instrument. ......view more

Technology / Differentiation

Cognoptix is developing technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye, to examine and measure deposits in specific areas of the lens as a means of earl...view more

Market / Customers

Alzheimer's Disease has long been recognized as a growing diagnostic and therapeutic challenge, with current medical detection methods limited to invasive, expensive, and unreliable tests that are una......view more